ERAS-801
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for ERAS-801, covering 2025-08-17 to 2026-04-07. Get the full timeline:
Most recent: Clinical Trial Update: ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial [Phase 1]